Tallahassee Journal

Behcet’s Syndrome Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Behcet’s Syndrome Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 23
21:15 2022
Behcet's Syndrome Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Behcet’s Syndrome Market
DelveInsight’s “Behçet syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Behçet syndrome, historical and forecasted epidemiology as well as the Behçet syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Behçet syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Behçet syndrome, historical and forecasted epidemiology as well as the Behçet syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Behçet syndrome Market Report:

  • Present in 40─70% of patients from the Middle East and Asia; however, it is found in only 13% of patients in Europe and North America. Oral ulcer is the most common manifestation of BD (found in 95─100% of patients) and can be the presenting manifestation in about 70% of patients. Oral ulcers are more common in females as compared to males.
  • As per a study conducted by  Oguz et al (2017), Bycet disease has a worldwide distribution. But it is commonly seen in the SAs per a study conducted by Comlekoglu et al (2014), HLA-B51 has been shown to be ilk Road countries around the Mediterranean Sea, including Spain, Japan, and others. The prevalence of Bycet disease in Japan was 7–13.5 per 100,000 cases whereas in Italy and Germany it was reported to be around 4.1–15.9 and 0.9 per 100,000 cases.
  • As per a study conducted by Hizli et al (2017), Behçet’s disease can be seen at any age, but it mostly appears between the second and fourth decades of life. In Germany, females were more predominant as compared to males (1.51:1.38)

Got queries? Click here to know more about the Behcet’s Syndrome market landscape

 

Behçet syndrome Overview

Behçet’s syndrome also known as Bycet disease is a rare chronic, relapsing and debilitating inflammatory multisystem disease of unknown etiology characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes.

Typically, painful canker sores on the mouth’s mucous membranes are Behçet’s syndrome’s first sign (aphthous stomatitis). The eyes may potentially be impacted by Behçet’s syndrome. Inflammation of the anterior chamber and the posterior uveitis are two symptoms that can occur (anterior uveitis or iridocyclitis). It is also possible for the iris to become inflamed and experience pain, tearing, and pus buildup (hypopyon iritis).

Due to the absence of any pathognomonic test findings, Behcet’s must be diagnosed clinically, which can be challenging. Leukocytosis, elevated inflammatory marker levels, and anaemia of chronic disease are examples of common, non-specific laboratory results. Imaging studies must focus on the affected organ and may include X-rays, arthrocentesis to evaluate arthritis, CT scans to evaluate for bleeding, thrombosis, and ischemia, angiography to look for aneurysms, and lumbar punctures to assess meningitis. Imaging studies must also be directed at the affected organ.

 

Behcet’s Syndrome Epidemiology Insights

 

  • According to Orphanet (2020), Behçet disease is a rare, chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular, and central nervous system manifestations.  It is most often reported in populations along the Silk Road. The total prevalence of Behcet’s disease in Japan was 1 per 10,000 cases.
  • As per Woźniacka et al (2015) study, the highest frequency of Behcet’s disease in the Western world is in the US, where the prevalence is 8.6 per 100,000 cases. Additionally, it is less frequently diagnosed in Europe: 0.64 per 100,000 for the United Kingdom, 3.7 per 100,000 for Italy, 5.6 per 100,000 for Spain, and 7.2 per 100,000 for France. 

 

  • As per Hammam et al (2021) study, the prevalence of BD in the US is increasing and patients are 

predominantly female as compared to males (3.8:1). Approximately, 79.3% were female predilection.

  •  As per Killan and Sawalha’s (2017) study, Behçet’s disease is heterogeneous with clinical variability across ethnicities and geographic locations. The prevalence of Behcet’s disease in US was 5.2 per 100,000 cases

 

  •  As per Kirino and Nakajima’s (2019) study, diagnosis of BD has become even more challenging in recent years in Japan and the rate of incomplete BD is increasing. The prevalence rate in Japan is about 16 per 100,000 cases. There is no marked gender difference in the overall disease, but arthritis and genital ulcer are more common in women, whereas central nervous system and eye lesions are more prevalent in men.

 

Behcet’s Syndrome Epidemiology Segmentation

 

  •  Behcet’s syndrome total Prevalent cases
  •  Behcet’s syndrome total Diagnosed cases
  •  Behcet’s syndrome total Gender-specific cases 
  •  Behcet’s syndrome total treated cases.

 

Behcet’s Syndrome Market Outlook 

The Behçet syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Behçet syndrome market trends by analyzing the impact of current Behçet syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Behçet syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Behçet syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Behçet syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Behcet’s Syndrome Market

 

Behcet’s Syndrome Key Companies

  • Jansen and Jansen 
  • Amgen 

 

Behcet’s Syndrome  Therapies

  •  OTEZLA (apremilast) – for Pediatric/ Adults 
  •  STELARA (ustekinumab)
  •  Immunosuppressants (Azathioprine, ciclosporin and others)

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Behcet’s Syndrome 
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Behcet’s Syndrome   Emerging Therapies
  • Behcet’s Syndrome Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Behcet’s Syndrome Report Methodology
  • DelveInsight Capabilities
  • Disclaimer

Click here to read more about Behcet’s Syndrome Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories